The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Trial design for a phase 3 study evaluating pemigatinib (INCB054828) versus gemcitabine plus cisplatin chemotherapy in first-line treatment of patients with cholangiocarcinoma with FGFR2 rearrangement.
 
Tanios S. Bekaii-Saab
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bayer (Inst); Bristol-Myers Squibb; Bristol-Myers Squibb (Inst); Celgene; Celgene (Inst); Genentech/Roche; Glenmark; Incyte (Inst); Ipsen (Inst); Lilly; Lilly (Inst); Merck (Inst); NCCN; Regeneron; Research to Practice; Roche/Genentech (Inst)
Research Funding - NCCN; NCI; Oncolytics
Other Relationship - ARMO BioSciences; Exelixis; Exelixis; Merck; Polaris; Sillajen
 
Juan W. Valle
Honoraria - Ipsen
Consulting or Advisory Role - Agios; AstraZeneca; Delcath Systems; Genoscience Pharma; Incyte; Ipsen; Keocyt; Merck; Novartis; PCI Biotech; Pfizer; Pieris Pharmaceuticals; QED Therapeutics
Speakers' Bureau - Ipsen; Novartis
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - Celgene; Nucana
 
Mitesh J. Borad
Stock and Other Ownership Interests - AVEO; Gilead Sciences; GlaxoSmithKline
Consulting or Advisory Role - Agios (Inst); ArQule (Inst); Celgene (Inst); Fujifilm (Inst); G1 Therapeutics; Halozyme (Inst); Inspyr Therapeutics; Insys Therapeutics (Inst); Novartis (Inst); Pieris Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); TD2
Research Funding - Agios (Inst); ARIAD (Inst); BiolineRx (Inst); Boston Biomedical (Inst); Celgene (Inst); Dicerna (Inst); Eisai (Inst); EMD Serono (Inst); Halozyme (Inst); ImClone Systems (Inst); Incyte (Inst); Incyte (Inst); Isis Pharmaceuticals (Inst); MedImmune (Inst); miRNA Therapeutics (Inst); Puma Biotechnology (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); Senhwa Biosciences (Inst); Sillajen (Inst); Sun Biopharma (Inst); Sun Biopharma (Inst); Taiho Pharmaceutical (Inst); Threshold Pharmaceuticals (Inst); Toray Industries (Inst)
Travel, Accommodations, Expenses - ArQule; AstraZeneca; Celgene
 
Davide Melisi
Consulting or Advisory Role - Baxter; Evotec; Incyte; Lilly; Shire
Research Funding - Celgene; Incyte; Shire
Travel, Accommodations, Expenses - Celgene
 
Arndt Vogel
Honoraria - Amgen; Bayer; Bristol-Myers Squibb; Delcath Systems; Lilly; MSD; Novartis; Roche; Sanofi
Consulting or Advisory Role - Amgen; Baxalta; Bayer; Delcath Systems; Lilly; Novartis; Roche
Research Funding - Novartis
Travel, Accommodations, Expenses - Bayer; Ipsen; Roche
 
Luis Féliz
Employment - Incyte
 
Christine Francis Lihou
Employment - Incyte
 
Huiling Zhen
Employment - Incyte
 
Ghassan K. Abou-Alfa
Consulting or Advisory Role - 3DMedcare; Agios; Alignmed; Amgen; Antengene; Aptus Clinical; ASLAN Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; BeiGene; BiolineRx (I); Boston Scientific; BridgeBio Pharma; Bristol-Myers Squibb; CARsgen Therapeutics; CASI Pharmaceuticals; Celgene; Celsion; Cipla; CytomX Therapeutics (I); Daiichi Sankyo; Debiopharm Group; Delcath Systems; Eisai; EMD Serono (I); Exelixis; Genoscience Pharma; Gilead Sciences (I); Halozyme; Halozyme; Hengrui Pharmaceutical; Inovio Pharmaceuticals; Ipsen; Janssen (I); Jazz Pharmaceuticals; Kyowa Hakko Kirin; LAM Therapeutics; Lilly; Loxo (I); Medimmune; Merck Serono; Minapharma; Newlink Genetics (I); Novella Clinical; Onxeo; PCI Biotech; PCI Biotech; Pfizer (I); Pharmacyclics (I); Pharmacyte Biotech (I); Pieris Pharmaceuticals (I); QED Therapeutics; RedHill Biopharma; Roche; Sanofi; SERVIER; Silenseed (I); Sillajen; Sirtex Medical; Sirtex Medical; SOBI (I); Targovax (I); Tekmira; Tekmira; twoXAR; Vicus Therapeutics (I); Yakult Pharmaceutical; Yakult Pharmaceutical; Yiviva
Research Funding - Acta Biologica (Inst); Agios (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); CASI Pharmaceuticals (Inst); Celgene (Inst); Exelixis (Inst); Genentech (Inst); Halozyme (Inst); Incyte (Inst); Lilly (Inst); MabVax (Inst); MedImmune (Inst); Momenta Pharmaceuticals (Inst); Novartis (Inst); OncoMed (Inst); OncoQuest (Inst); Polaris (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); QED Therapeutics (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Polaris